Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8852W HIGH $12.90
Volume
8.00 K
Value Traded
559.71 K
Short % Float
2.67%
-4.13%Week
-0.88%1 Month
+39.15%3 Month
-16.05%6 Month
-91.99%5 Year
-98.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
31.80 M
EPS (TTM)
-1.26
P/E Ratio
-
Ent. Value
16.01 M
Total Shares
4.03 M
Float Shares
3.37 M
Insiders
16.37%
Institutions
8.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RMTI Catalyst Timeline
Dated clinical, regulatory and corporate events for Rockwell Medical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rockwell Medical, Inc.
594Total events
1Upcoming
114Tier-1 (high impact)
2007 to 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 50
▲Quarterly UpdateCorporate
Preliminary unaudited Q4 and full-year 2025 financial results reported
▲Partnership / LicenseCorporate
Amended and Restated Product Purchase Agreement extended through December 31, 2026 with one of the largest US dialysis providers
hemodialysissource ↗
◆Quarterly UpdateCorporate
Full-year 2023 financial results expected to be reported in March 2024
▲Debt Royalty FinancingCorporate
Amended loan and security agreement with Innovatus, extending maturity to Jan 2029 and reducing interest rate
◆Quarterly UpdateCorporate
2024 guidance: net sales $84-88M, gross profit $12-14M, adjusted EBITDA $0-0.5M
▲Quarterly UpdateCorporate
Q4 2023 financial results: achieved profitability on adjusted EBITDA basis
▲Quarterly UpdateCorporate
Expanded international footprint with distribution agreements in UAE, Chile, St. Lucia, Costa Rica, Grenada
▲Partnership / LicenseCorporate
Entered into three-year co-promotion services agreement with B. Braun Medical Inc.
▲Other Regulator MilestoneEx-US Regulatory
Rockwell Transportation received highest safety rating from FMCSA
▲AcquisitionCorporate
Rockwell Medical acquires hemodialysis concentrates business from Evoqua Water Technologies
hemodialysissource ↗
▲Quarterly UpdateCorporate
Rockwell Medical increases 2023 revenue guidance to $82-86 million
▼Restructuring LayoffsCorporate
Workforce and cost reductions undertaken as part of business restructuring
◆Topline ReadoutFPCFiledClinical Data
Multiple data readouts anticipated in 2023
iron deficiency anemiasource ↗
◆Trial InitiationFPCFiledTrial
Phase 2 trial for home infusion iron therapy expected to start in 2H 2022
iron deficiency anemiasource ↗
▲Quarterly UpdateCorporate
Expect positive gross margin from dialysis concentrates beginning 2H 2022
◆First Patient Dosedsoluble ferric pyrophosphateApprovedTrial
First patient dosing expected after additional data submission and 30-day FDA review
iron deficiency anemia in home infusionsource ↗
▲Product LaunchTrifericApprovedPost-Market
Commercial launch of Triferic AVNU in South Korea
iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney diseasesource ↗
◆Trial InitiationFPCFiledTrial
Phase 2 trial for home infusion iron therapy expected to start in H2 2022
iron deficiency anemiasource ↗
●Poster PresentationPresentation
Poster presentation at NHIA 2022 Annual Conference
Iron Deficiency Anemiasource ↗
▲Other Regulator MilestoneTrifericApprovedEx-US Regulatory
Regulatory approval of Triferic Dialysate in South Korea
hemodialysis-dependent chronic kidney disease (HDD-CKD)source ↗
▲Other Regulator MilestoneTrifericApprovedEx-US Regulatory
MFDS approval of Triferic AVNU in South Korea
iron supplementation therapy and maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney diseasesource ↗
◆Trial InitiationFPCFiledTrial
Phase II trial for FPC in iron deficiency anemia expected to start
iron deficiency anemiasource ↗
◆Product LaunchTrifericApprovedPost-Market
Expected commercial availability of Triferic AVNU in Canada
replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney diseasesource ↗
◆Product LaunchTrifericApprovedPost-Market
Product sales anticipated to begin in South Korea
iron deficiency and anemia in hemodialysis patientssource ↗
◆FDA Feedback Receivedsoluble ferric pyrophosphateApprovedFDA Meeting
FDA feedback on IND for Phase 2 trial of FPC in home infusion
iron deficiency anemia in home infusionsource ↗
●IND Submissionsoluble ferric pyrophosphateApprovedIND
IND submission for Phase 2 trial of FPC in home infusion
iron deficiency anemia in home infusionsource ↗
◆Topline ReadoutFPCFiledClinical Data
Phase II data readout for home infusion program
iron deficiency anemia in home infusion patientssource ↗
▲Full Resultssoluble ferric pyrophosphateApprovedClinical Data
Publication of study results demonstrating no drug-drug interaction between FPC and unfractionated heparin
Hemodialysis Dependent Chronic Kidney Diseasesource ↗
◆Quarterly UpdateCorporate
Third Quarter 2021 Financial and Operating Results Conference Call
●IND SubmissionFPCFiledIND
Submitted IND for FPC as treatment for IDA in home infusion patients
iron deficiency anemia in patients receiving home infusionsource ↗
●IND Submissionsoluble ferric pyrophosphateApprovedIND
IND submission for FPC home infusion program
iron deficiency anemia in patients receiving home infusionsource ↗
Past FDA Catalysts and PDUFA Decisions
How RMTI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-03-27 | Triferic Avnu (ferric pyrophosphate citrate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
9
Drugs Scored
-
rNPV / MCap
Top 79%
Micro Cap(rank 522 of 660)
Percentile Rank
Rockwell Medical, Inc. faces pipeline headwinds (26/100), with 9 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every RMTI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Ferric Pyrophosphate Citrate | Hemodialysis Dependent Chronic Kidney Disease | 2021-11-16 | mean anti-Xa activity, activated prothrombin time (aPTT), Thrombin time (TT) concentrations were comparable across all timepoints at baseline, and throughout the study; more than 1.6mm million doses have been safely administeredRead More | Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated HeparinRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Strobeck MarkDirector, Officer (President and CEO) | Sell | -1,000 61,349 held | $8.42 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RMTI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RMTI for Q2 2026. | ||||
RMTI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RMTI ranks across every disease it competes in
Competitive Position is a premium feature
See how RMTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRMTI News
RMTI▲ +7.5%on this news
Rockwell Medical Ranked No. 16 on the 2026 Fortune ‘Best Workplaces in Manufacturing & Production’ List
Rockwell Medical has been ranked No. 16 on the 2026 Fortune 'Best Workplaces in Manufacturing & Production' list. This achievement marks the third consecutive year of recognition for the company, showcasing a significant improvement from its previous rankings of #50 in 2024 and #40 in 2025. The company's commitment to creating a positive work environment is evident in its rising status.
Read more →RMTIRockwell Medical Announces Second Quarter 2026 Results
Rockwell Medical has announced its financial results for the second quarter of 2026, showcasing significant year-over-year growth. The company also reported an expansion in gross margin, reflecting enhanced profitability. Additionally, Rockwell Medical generated positive operating cash flow during this period.
Read more →RMTIRockwell Medical Advances Quality and Regulatory Leadership
Rockwell Medical has appointed Brian Cox as the new Vice President of Quality and Regulatory Compliance. With over 20 years of experience in healthcare, Cox is expected to enhance the company's leadership in quality and regulatory matters. This move is seen as a strategic advancement for Rockwell Medical.
Read more →RMTIRockwell Medical Regains Compliance with Nasdaq Listing Requirements
Rockwell Medical has successfully regained compliance with Nasdaq's minimum bid price requirement, as per Nasdaq Listing Rule 5550(a)(2). This development is expected to bolster investor confidence and may have a positive effect on the company's stock performance.
Read more →RMTIRockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
Rockwell Medical has announced that it will release its financial results for the second quarter of 2026, which ended on June 30, 2026. The results will be made public on Thursday, August 13, 2026. This announcement is part of the company's ongoing commitment to transparency in its financial reporting.
Read more →RMTI▼ -9.8%on this news
Rockwell Medical Announces 1-for-10 Reverse Stock Split
Rockwell Medical has announced a 1-for-10 reverse stock split. This decision is part of the company's strategy to improve its stock price and meet listing requirements. The reverse split will reduce the number of shares outstanding while increasing the share price proportionately.
Read more →RMTIRockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026
Rockwell Medical, Inc. will announce its financial and operational results for Q4 and the full year of 2025 on March 26, 2026. The announcement will include a press release at 6:00am ET and a live webcast at 8:00am ET. The company emphasizes its commitment to providing high-quality hemodialysis products and exceptional customer service.
Read more →RMTI▼ -6.4%on this news
Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row
Rockwell Medical has been certified as a Great Place to Work for the fourth consecutive year. This recognition highlights the company's commitment to fostering a supportive and empowering workplace culture. The Vice President of Human Resources emphasized the importance of their dedicated employees in driving the company's mission and values. Rockwell Medical continues to focus on innovation and delivering quality products to dialysis providers.
Read more →RMTI▲ +31.6%on this news
Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results
Rockwell Medical, Inc. reported preliminary unaudited financial results for Q4 and full-year 2025, highlighting a significant revenue increase and positive cash flow. The company achieved an Adjusted EBITDA positive status and improved its gross margin to 22%. Looking ahead, Rockwell aims to focus on revenue growth, profitability, and diversification of its product portfolio.
Read more →RMTI▲ +14.4%on this news
Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States
Rockwell Medical has extended its product purchase agreement with a major U.S. dialysis provider through December 31, 2026. The amended agreement includes increased pricing for products, highlighting the importance of Rockwell's reliable supply chain and high-quality offerings. The company's leadership expresses optimism about strengthening the partnership further.
Read more →RMTI▼ -7.1%on this news
Rockwell Medical Announces First Quarter 2025 Results Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit o
Rockwell Medical, Inc. reported its financial and operational results for the first quarter of 2025, highlighting a 17% decrease in net sales to $18.9 million compared to $22.7 million in the same period of 2024. The company recorded an operating loss of $1.360 million, slightly higher than the $1.324 million loss in Q1 2024. Despite the decrease in sales and losses, Rockwell Medical remains committed to business growth and diversification, maintaining its 2025 annual guidance for net sales and gross margin.
Read more →RMTI▼ -20.5%on this news· ran to -32% by day 3
Rockwell Medical Announces Fourth Quarter and Financial and Operational Results
Rockwell Medical, Inc. announced its financial results for the fourth quarter and full year of 2024, highlighting its first-ever adjusted EBITDA profitability. The company achieved net sales exceeding $100 million and improved gross margins. Looking ahead, Rockwell expects 2025 to be a transitional year, indicating potential challenges in maintaining current sales levels due to changes in its customer base. The company remains focused on sustaining profitability and optimizing its operations.
Read more →RMTI▼ -7.9%on this news
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023 Reports record net sales for second year in a row,
Rockwell Medical announced significant financial results for the fourth quarter and full year of 2023, achieving profitability on an adjusted EBITDA basis for the first time in its history. The company reported record net sales of $84 million to $88 million for 2024, alongside an increase in gross profit. Mark Strobeck, CEO, noted improvements in financial health and operational efficiencies, which they expect to sustain and build upon in the coming years. Rockwell Medical is focused on enhancing its product offerings and expanding its market presence domestically and internationally.
Read more →RMTI▼ -5.7%on this news
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enh
Rockwell Medical, Inc. has amended its loan agreement with Innovatus Life Sciences Lending Fund, deferring $8 million in principal payments for up to three years and reducing its interest rate. The company expects to achieve better financial flexibility and enhance its cash balance as it moves towards profitability. Additionally, preliminary projections for Q4 2023 indicate a significant increase in net sales compared to the previous year. However, Rockwell is still forecasting net losses for both the fourth quarter and the full year.
Read more →RMTIRockwell Medical Announces Third Quarter 2023 Results Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-d
Rockwell Medical, Inc. announced its financial results for the third quarter of 2023, reporting net sales of $23.8 million, the highest in its history. This achievement marks a significant increase from the previous year, driven by strategic enhancements in its business model and substantial growth in its hemodialysis concentrates segment. The company anticipates continued growth, projecting net sales to be between $82.0 million and $86.0 million for 2023, alongside expected gross profit increases. Despite reporting a net loss, Rockwell Medical is on target for profitability in the fourth quarter of 2023.
Read more →RMTIDocument Rockwell Medical Announces Second Quarter 2023 Results Net sales for the six months ended
Rockwell Medical reported its second quarter earnings for 2023, showing an 8% increase in net sales to $37.7 million and a significant rise in gross profit by 260% to $3.6 million. Following its acquisition of Evoqua's hemodialysis concentrates business, the company has raised its 2023 net sales guidance, now anticipating between $82 million and $86 million. Rockwell Medical plans to achieve profitability by the fourth quarter of 2023, positioning itself for stronger growth in the future. However, it also noted a continued net loss, which was down compared to the previous year, but slightly increased quarter-over-quarter.
Read more →RMTI▼ -7.4%on this news· ran to -48% by day 3
Rockwell Medical Acquires Hemodialysis Concentrates Business from Evoqua Water Technologies Adds profitable business that generates approximately $18 million in annual revenue and will add over $3.3 million in annual EBI
Rockwell Medical, Inc. has acquired the hemodialysis concentrates business from Evoqua Water Technologies for $11 million plus milestone payments. This acquisition is projected to generate approximately $18 million in annual revenue and an additional $3.3 million in EBITDA. The deal expands Rockwell's market presence and customer base, enabling it to become a leading supplier of hemodialysis products in the United States. The firm has adjusted its revenue guidance for 2023 to reflect this impactful acquisition.
Read more →RMTIRockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer WIXOM, Mich., June 22, 2022 -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, t
Read more →RMTIRockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation June 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statement
Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation June 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including
Read more →About Rockwell Medical, Inc.
Headquarters30142 WIXOM ROAD, WIXOM, MI, 48393
BIOPHARMAWATCH ELITE PLUS
Trade the next RMTI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime